dc.contributor.author | Bulur, Işıl | |
dc.contributor.author | Bülbül Başkan, Emel | |
dc.contributor.author | Özdemir, Mustafa | |
dc.contributor.author | Balevi, Ali | |
dc.contributor.author | Kocatürk Göncü, Emek | |
dc.contributor.author | Kıvanç Altunay, İlknur | |
dc.contributor.author | Gönül, Müzeyyen | |
dc.contributor.author | Ergin, Can | |
dc.contributor.author | Ertam, İlgen | |
dc.contributor.author | Kaya Erdoǧan, Hilal | |
dc.contributor.author | Bilgin, Muzaffer | |
dc.contributor.author | Erdem, Mustafa Teoman | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:36:17Z | |
dc.date.available | 10.07.201910:49:14 | |
dc.date.available | 2019-07-10T19:36:17Z | |
dc.date.issued | 2018 | en_US |
dc.identifier.citation | Bulur, I., Bülbül Başkan, E., Özdemir, M., Balevi, A., Kocatürk Göncü, E., Kıvanç Altunay, İ. ... Erdem, M. T. (2018). The efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey. Acta Dermatovenerologica Alpina, Pannonica et Adriatica, 27(3), 121-126. https://dx.doi.org/10.15570/actaapa.2018.25 | en_US |
dc.identifier.issn | 1318-4458 | |
dc.identifier.issn | 1581-2979 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/1120 | |
dc.identifier.uri | https://dx.doi.org/10.15570/actaapa.2018.25 | |
dc.description.abstract | Introduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients. Methods: Study data were collected retrospectively from eight tertiary-care hospitals in Turkey. This study included 132 patients with chronic spontaneous urticaria that were resistant to H1 antihistamine treatment in a dose up to four times the licensed dose and were treated with 300 mg/month of omalizumab for 6 months. Results: The mean weekly urticarial activity score (UAS7) after omalizumab treatment improved significantly compared to the pretreatment score (p <0.001). Treatment response was detected primarily in the 1st and 2nd months after treatment. No significant association was observed between omalizumab’s treatment effectiveness and disease-related parameters or laboratory data. The mean dermatology life quality index was 23.12 ± 6.15 before treatment and decreased to 3.55 ± 3.60 6 months after treatment (p <0.001). No side effects were reported in 89.4% (118) of the patients. Conclusion: This study showed that UAS7 decreased significantly and quality of life improved in omalizumab-treated patients. Moreover, treatment effectiveness was mainly observed in the first 2 months after treatment. However, no association was observed between omalizumab treatment effectiveness and disease-related parameters or laboratory data. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Slovenian Medical Society | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Chronic Spontaneous Urticaria | en_US |
dc.subject | Dermatology Life Quality | en_US |
dc.subject | Omalizumab | en_US |
dc.subject | Side Effect | en_US |
dc.subject | UAS7 | en_US |
dc.title | The efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Acta Dermatovenerologica Alpina, Pannonica et Adriatica | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıklar Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-7022-913X | en_US |
dc.authorid | 0000-0001-5057-0405 | en_US |
dc.identifier.volume | 27 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 121 | en_US |
dc.identifier.endpage | 126 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.15570/actaapa.2018.25 | en_US |